Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank.

International journal of chronic obstructive pulmonary disease - 1 Jan 2009

Tonelli Adriano R, Rouhani Farshid, Li Ning, Schreck Pam, Brantly Mark L

Abstract excerpt

INTRODUCTION: Intravenous augmentation therapy with purified intravenous alpha-1 antitrypsin replaces the deficient protein and is the only currently approved treatment for alpha-1 antitrypsin deficiency (AATD) related lung disease. While augmentation therapy has been available for more than 20 years, there are a limited number of studies evaluating the effect of augmentation on lung function. MATERIAL AND...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha 1-Antitrypsin Deficiency
Share to Enzyme Replacement Therapy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Forced Expiratory Volume

Share to Injections, Intravenous

Share to Recovery of Function

Share to Smoking Cessation

Share to Spirometry

Share to Tissue Banks

Source

Open in PubMed Open full text

Identifiers

PMID: 20054436
DOI: 10.2147/copd.s8577
PMCID: PMC2802045

Genes

FEV

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank.PMID 20054436Read ↗

Alpha-1 Antitrypsin Augmentation TherapySemantic proximity Read ↗

Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data.Semantic proximity Read ↗

Augmentation Therapy for Severe Alpha-1 Antitrypsin Deficiency Improves Survival and Is Decoupled from Spirometric Decline-A Multinational Registry Analysis.Semantic proximity Read ↗

[Alpha-1-antitrypsin deficiency - an update].Semantic proximity Read ↗

alpha1-Antitrypsin deficiency . 6: new and emerging treatments for alpha1-antitrypsin deficiency.Semantic proximity Read ↗

Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group.Semantic proximity Read ↗

Alpha-1 antitrypsin deficiency: outstanding questions and future directionsSemantic proximity Read ↗

α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.Semantic proximity Read ↗

A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy.Semantic proximity Read ↗

Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events.Semantic proximity Read ↗

Diagnosing alpha-1 antitrypsin deficiency: the first step in precision medicineSemantic proximity Read ↗

Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.